At the time of surgery, patients must have a unilateral supratentorial tumor, measuring at least 1.0 cm in diameter, as determined by contrast-enhanced CT or MRI scanning.
Surgical treatment is indicated at the time of baseline evaluation.
Patients must have a Karnofsky Performance Score of 60 or higher at the baseline visit and pre-operatively on the day of surgery. All patients, both men and women, must be willing to practice an effective method of birth control during the study. Patients with more than one focus of tumor or tumor crossing the midline will be ineligible Patients with concomitant significant life-threatening disease which could reasonably cause the patient to die within the first 56 days of the study would be ineligible. Patients with fewer than 100,000 platelets per mm3 or fewer than 3,500 leukocytes per mm3 would be ineligible. Patient will have repeat surgery to remove as much tumor as possible, whether participation in this study is selected or not.